{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:12:29Z","timestamp":1791573149317,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02712-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:02:25Z","timestamp":1778112145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming"],"prefix":"10.1038","volume":"11","author":[{"given":"Laiyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zherui","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youling","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming Spring","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Niedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2712_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838\u2013857 (2021).","journal-title":"Cancer Discov."},{"key":"2712_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2712_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1158\/1078-0432.CCR-22-1591","volume":"29","author":"R Luo","year":"2023","unstructured":"Luo, R. et al. Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect. Clin. Cancer Res. 29, 667\u2013683 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2712_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450\u2013462 (2021).","journal-title":"Lancet Oncol."},{"key":"2712_CR5","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1200\/JCO-25-00036","volume":"43","author":"JD Bradley","year":"2025","unstructured":"Bradley, J. D. et al. Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study. J. Clin. Oncol. 43, 3610\u20133621 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen, W. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276\u20131282 (2019).","journal-title":"JAMA Oncol."},{"key":"2712_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001001","volume":"8","author":"J Welsh","year":"2020","unstructured":"Welsh, J. et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial. J. Immunother. Cancer 8, e001001 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2712_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30\u201337 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2712_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","volume":"400","author":"S Kim","year":"2022","unstructured":"Kim, S. et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet 400, 1008\u20131019 (2022).","journal-title":"Lancet"},{"key":"2712_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","volume":"9","author":"M Spaas","year":"2023","unstructured":"Spaas, M. et al. Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial. JAMA Oncol. 9, 1205\u20131213 (2023).","journal-title":"JAMA Oncol."},{"key":"2712_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","volume":"405","author":"II Verginadis","year":"2025","unstructured":"Verginadis, I. I. et al. Radiotherapy toxicities: mechanisms, management, and future directions. Lancet 405, 338\u2013352 (2025).","journal-title":"Lancet"},{"key":"2712_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","volume":"108","author":"L Yin","year":"2020","unstructured":"Yin, L. et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 108, 212\u2013224 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2712_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589\u2013602 (2013).","journal-title":"Cancer Cell"},{"key":"2712_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108\u2013133 (2022).","journal-title":"Cancer Discov."},{"key":"2712_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000537","volume":"8","author":"HB Barsoumian","year":"2020","unstructured":"Barsoumian, H. B. et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J. Immunother. Cancer 8, e000537 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2712_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43462-1","volume":"14","author":"S Li","year":"2023","unstructured":"Li, S. et al. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nat. Commun. 14, 7709 (2023).","journal-title":"Nat. Commun."},{"key":"2712_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589\u2013602 (2013).","journal-title":"Cancer Cell"},{"key":"2712_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","volume":"23","author":"JD Schoenfeld","year":"2022","unstructured":"Schoenfeld, J. D. et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23, 279\u2013291 (2022).","journal-title":"Lancet Oncol."},{"key":"2712_CR19","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-20-4632","volume":"27","author":"AM Monjazeb","year":"2021","unstructured":"Monjazeb, A. M. et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer. Clin. Cancer Res. 27, 2470\u20132480 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2712_CR20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nri1245","volume":"3","author":"JB Huppa","year":"2003","unstructured":"Huppa, J. B. & Davis, M. M. T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3, 973\u2013983 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"2712_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","volume":"39","author":"J Duraiswamy","year":"2021","unstructured":"Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623\u20131642.e1620 (2021).","journal-title":"Cancer Cell"},{"key":"2712_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","volume":"44","author":"Y Liu","year":"2026","unstructured":"Liu, Y., Dai, Y. & Wang, L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell 44, 24\u201349 (2026).","journal-title":"Cancer Cell"},{"key":"2712_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"2712_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick, C. C. & Malanchi, I. Neutrophils in cancer: heterogeneous and multifaceted. Nat. Rev. Immunol. 22, 173\u2013187 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2712_CR25","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese, M. A., Hind, L. E. & Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 133, 2159\u20132167 (2019).","journal-title":"Blood"},{"key":"2712_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","volume":"14","author":"S Xiong","year":"2021","unstructured":"Xiong, S., Dong, L. & Cheng, L. Neutrophils in cancer carcinogenesis and metastasis. J. Hematol. Oncol. 14, 173 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2712_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02004-z","volume":"23","author":"X Huang","year":"2024","unstructured":"Huang, X. et al. Neutrophils in cancer immunotherapy: friends or foes? Mol. Cancer 23, 107 (2024).","journal-title":"Mol. Cancer"},{"key":"2712_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon, J. et al. A neutrophil response linked to tumor control in immunotherapy. Cell 186, 1448\u20131464.e1420 (2023).","journal-title":"Cell"},{"key":"2712_CR29","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn, D. et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186, 1432\u20131447.e1417 (2023).","journal-title":"Cell"},{"key":"2712_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fimmu.2017.00828","volume":"8","author":"G Genard","year":"2017","unstructured":"Genard, G., Lucas, S. & Michiels, C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front. Immunol. 8, 828 (2017).","journal-title":"Front. Immunol."},{"key":"2712_CR31","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","volume":"73","author":"J Xu","year":"2013","unstructured":"Xu, J. et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73, 2782\u20132794 (2013).","journal-title":"Cancer Res."},{"key":"2712_CR32","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","volume":"21","author":"A Filatenkov","year":"2015","unstructured":"Filatenkov, A. et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin. Cancer Res. 21, 3727\u20133739 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2712_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Investig. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Investig."},{"key":"2712_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijrobp.2020.07.2321","volume":"109","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Single high-dose radiation enhances dendritic cell homing and t cell priming by promoting reactive oxygen species-induced cytoskeletal reorganization. Int. J. Radiat. Oncol. Biol. Phys. 109, 95\u2013108 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2712_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1667\/RR14840.1","volume":"189","author":"N Yu","year":"2018","unstructured":"Yu, N. et al. Low-dose radiation promotes dendritic cell migration and IL-12 production via the ATM\/NF-KappaB pathway. Radiat. Res. 189, 409\u2013417 (2018).","journal-title":"Radiat. Res."},{"key":"2712_CR36","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1901562116","volume":"116","author":"AJ Wisdom","year":"2019","unstructured":"Wisdom, A. J. et al. Neutrophils promote tumor resistance to radiation therapy. Proc. Natl. Acad. Sci. USA 116, 18584\u201318589 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2712_CR37","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-23-3860","volume":"30","author":"A Teijeira","year":"2024","unstructured":"Teijeira, A. et al. Low-dose ionizing gamma-radiation elicits the extrusion of neutrophil extracellular traps. Clin. Cancer Res. 30, 4131\u20134142 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2712_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-022-01307-2","volume":"15","author":"L Xu","year":"2022","unstructured":"Xu, L. et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J. Hematol. Oncol. 15, 87 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2712_CR39","first-page":"100205","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield, A. S. et al. Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin. Res. Rep. 2, 100205 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"2712_CR40","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell, S. F. et al. Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J. Thorac. Oncol. 16, 1883\u20131892 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2712_CR41","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-23-0315","volume":"29","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-naive stage IV PD-L1+ non-small cell lung cancer patients. Clin. Cancer Res. 29, 4098\u20134108 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2712_CR42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","volume":"42","author":"M Benguigui","year":"2024","unstructured":"Benguigui, M. et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 42, 253\u2013265.e212 (2024).","journal-title":"Cancer Cell"},{"key":"2712_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","volume":"30","author":"S Singhal","year":"2016","unstructured":"Singhal, S. et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30, 120\u2013135 (2016).","journal-title":"Cancer Cell"},{"key":"2712_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58510-1","volume":"16","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Combination radiation and alphaPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node. Nat. Commun. 16, 3522 (2025).","journal-title":"Nat. Commun."},{"key":"2712_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.immuni.2007.12.016","volume":"28","author":"A Scholer","year":"2008","unstructured":"Scholer, A. et al. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity 28, 258\u2013270 (2008).","journal-title":"Immunity"},{"key":"2712_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/(SICI)1096-9098(199709)66:1<39::AID-JSO8>3.0.CO;2-O","volume":"66","author":"J Turner","year":"1997","unstructured":"Turner, J., Rhee, J. G., Fabian, D. F. & Lefor, A. T. Expression of ICAM-1 enhances in vivo lymphocyte adhesion in a murine fibrosarcoma. J. Surg. Oncol. 66, 39\u201344 (1997).","journal-title":"J. Surg. Oncol."},{"key":"2712_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ijrobp.2018.10.009","volume":"103","author":"E Markovsky","year":"2019","unstructured":"Markovsky, E. et al. An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models. Int. J. Radiat. Oncol. Biol. Phys. 103, 697\u2013708 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2712_CR48","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunpaa","year":"2019","unstructured":"Harjunpaa, H., Llort Asens, M., Guenther, C. & Fagerholm, S. C. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol. 10, 1078 (2019).","journal-title":"Front. Immunol."},{"key":"2712_CR49","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.4049\/jimmunol.1201954","volume":"191","author":"NA Zumwalde","year":"2013","unstructured":"Zumwalde, N. A., Domae, E., Mescher, M. F. & Shimizu, Y. ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation. J. Immunol. 191, 3681\u20133693 (2013).","journal-title":"J. Immunol."},{"key":"2712_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Liu, X., Chen, D. & Yu, J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target. Ther. 7, 258 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2712_CR51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2712_CR52","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/cac2.12226","volume":"41","author":"S Shang","year":"2021","unstructured":"Shang, S. et al. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun. 41, 1086\u20131099 (2021).","journal-title":"Cancer Commun."},{"key":"2712_CR53","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cac2.12348","volume":"42","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Pivotal roles of tumor-draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy. Cancer Commun. 42, 971\u2013986 (2022).","journal-title":"Cancer Commun."},{"key":"2712_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","volume":"16","author":"ED Brooks","year":"2019","unstructured":"Brooks, E. D. & Chang, J. Y. Time to abandon single-site irradiation for inducing abscopal effects. Nat. Rev. Clin. Oncol. 16, 123\u2013135 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2712_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour, S. K. et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 7, 1\u20139 (2021).","journal-title":"JAMA Oncol."},{"key":"2712_CR56","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342\u20132350 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2712_CR57","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"2712_CR58","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel, S. et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38, 1505\u20131517 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2712_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen, W. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9, 467\u2013475 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2712_CR60","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou, Y., Shen, G., Zhou, X. & Li, J. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct. Target. Ther. 10, 178 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2712_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s43018-022-00336-7","volume":"3","author":"E Nolan","year":"2022","unstructured":"Nolan, E. et al. Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization. Nat. Cancer 3, 173\u2013187 (2022).","journal-title":"Nat. Cancer"},{"key":"2712_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53015-9","volume":"15","author":"P Bergeron","year":"2024","unstructured":"Bergeron, P. et al. Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade. Nat. Commun. 15, 8845 (2024).","journal-title":"Nat. Commun."},{"key":"2712_CR63","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell 187, 1422\u20131439.e1424 (2024).","journal-title":"Cell"},{"key":"2712_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.devcel.2024.10.010","volume":"60","author":"Z Tang","year":"2025","unstructured":"Tang, Z. et al. A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression. Dev. Cell 60, 379\u2013395.e378 (2025).","journal-title":"Dev. Cell"},{"key":"2712_CR65","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.ccell.2024.08.008","volume":"42","author":"M Lad","year":"2024","unstructured":"Lad, M. et al. Glioblastoma induces the recruitment and differentiation of dendritic-like \u201chybrid\u201d neutrophils from skull bone marrow. Cancer Cell 42, 1549\u20131569.e1516 (2024).","journal-title":"Cancer Cell"},{"key":"2712_CR66","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-025-08994-0","volume":"643","author":"A Piffko","year":"2025","unstructured":"Piffko, A. et al. Radiation-induced amphiregulin drives tumour metastasis. Nature 643, 810\u2013819 (2025).","journal-title":"Nature"},{"key":"2712_CR67","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ccell.2025.02.024","volume":"43","author":"YP Zhang","year":"2025","unstructured":"Zhang, Y. P. et al. PAI-1-driven SFRP2(high) cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer Cell 43, 856\u2013874.e859 (2025).","journal-title":"Cancer Cell"},{"key":"2712_CR68","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/ijc.34801","volume":"154","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Low-dose radiation therapy mobilizes antitumor immunity: new findings and future perspectives. Int. J. Cancer 154, 1143\u20131157 (2024).","journal-title":"Int. J. Cancer"},{"key":"2712_CR69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","volume":"43","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell 43, 361\u2013379.e310 (2025).","journal-title":"Cancer Cell"},{"key":"2712_CR70","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1038\/bjc.2014.163","volume":"110","author":"S Krenn-Pilko","year":"2014","unstructured":"Krenn-Pilko, S. et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br. J. Cancer 110, 2524\u20132530 (2014).","journal-title":"Br. J. Cancer"},{"key":"2712_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/srep22089","volume":"6","author":"X Gu","year":"2016","unstructured":"Gu, X. et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci. Rep. 6, 22089 (2016).","journal-title":"Sci. Rep."},{"key":"2712_CR72","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/bjc.2016.23","volume":"114","author":"T Grenader","year":"2016","unstructured":"Grenader, T. et al. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study. Br. J. Cancer 114, 612\u2013615 (2016).","journal-title":"Br. J. Cancer"},{"key":"2712_CR73","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/hepr.12436","volume":"45","author":"T Terashima","year":"2015","unstructured":"Terashima, T. et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol. Res. 45, 949\u2013959 (2015).","journal-title":"Hepatol. Res."},{"key":"2712_CR74","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218\u2013230 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2712_CR75","doi-asserted-by":"publisher","first-page":"e094859","DOI":"10.1136\/bmjopen-2024-094859","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang, R., Chen, M., Yin, N. & Xue, J. Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study). BMJ Open 15, e094859 (2025).","journal-title":"BMJ Open"},{"key":"2712_CR76","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41587-021-00830-w","volume":"40","author":"DM Cable","year":"2022","unstructured":"Cable, D. M. et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat. Biotechnol. 40, 517\u2013526 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2712_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 15, 14 (2023).","journal-title":"Genome Med."},{"key":"2712_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41588-023-01588-4","volume":"56","author":"M Varrone","year":"2024","unstructured":"Varrone, M. et al. CellCharter reveals spatial cell niches associated with tissue remodeling and cell plasticity. Nat. Genet. 56, 74\u201384 (2024).","journal-title":"Nat. Genet."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02712-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02712-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02712-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:02:27Z","timestamp":1778112147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02712-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02712-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}